'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Sun Pharmaceutical Industries has increased 9.47% to Rs 13851.4 crore. Operating profit margin has jumped from 28.51% to 31.06%, leading to 19.24% rise in operating profit to Rs 4,301.66 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 12.42% to 12.79%. Purchase of finished goods cost fell from 7.96% to 7.56%. Employee cost increased from 19.59% to 20.22%. Other expenses fell from 31.24% to 28.39%. Loss on forex transaction rose from 0.40% to 1.65%.
Other income fell 12.79% to Rs 464.46 crore. PBIDT rose 15.12% to Rs 4766.12 crore. Provision for interest rose 21.55% to Rs 74.8 crore.
PBDT rose 15.02% to Rs 4691.32 crore. Provision for depreciation ros...
Pleaselogin & subscribe to view the full report.
More Reports
|
|